NPC
MCID: NSP012
MIFTS: 60

Nasopharyngeal Carcinoma (NPC)

Categories: Cancer diseases, Gastrointestinal diseases, Genetic diseases, Oral diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Nasopharyngeal Carcinoma

MalaCards integrated aliases for Nasopharyngeal Carcinoma:

Name: Nasopharyngeal Carcinoma 57 12 73 20 58 29 13 54 6 15 39 70
Malignant Neoplasm of Nasopharynx 12 70 32
Nasopharyngeal Cancer 57 20 36
Nasopharyngeal Neoplasms 44 70
Nasopharynx Carcinoma 12 15
Npc 57 17
Squamous Cell Carcinoma of the Nasopharynx 58
Malignant Nasopharyngeal Tumor 12
Nasopharyngeal Carcinoma 1 57
Carcinoma of Nasopharynx 12
Nasopharyngeal Neoplasm 17
Cancer of Nasopharynx 70
Nasopharynx Cancer 12
Npca 57

Characteristics:

Orphanet epidemiological data:

58
nasopharyngeal carcinoma
Inheritance: Multigenic/multifactorial,Not applicable; Prevalence: 1-9/100000 (Europe); Age of onset: All ages;

HPO:

31
nasopharyngeal carcinoma:
Inheritance polygenic inheritance


Classifications:

Orphanet: 58  
Rare respiratory diseases


External Ids:

Disease Ontology 12 DOID:9261
OMIM® 57 607107
KEGG 36 H00054
MeSH 44 D009303
NCIt 50 C9321
MESH via Orphanet 45 C538339
ICD10 via Orphanet 33 C11.0 C11.1 C11.2 more
UMLS via Orphanet 71 C0153392 C0238301 C2931822
Orphanet 58 ORPHA150
MedGen 41 C2931822
SNOMED-CT via HPO 68 126680004
UMLS 70 C0027439 C0153392 C0153393 more

Summaries for Nasopharyngeal Carcinoma

KEGG : 36 Nasopharyngeal carcinoma (NPC) is a rare disease in most parts of the world, with an age-standardised annual incidence of less than 1 per 100000. However, in Southern China, parts of Southeast Asia and the Mediterranean basin, NPC is an endemic disease with an incidence of 10-30 per 100000. Genome-wide studies have unravelled multiple chromosomal abnormalities with involvement of specific oncogenes and tumor suppressor genes. Alterations of genes such as Ras association domain family 1A (RASSF1A), p16/INK4A, p14/ARF suggest that multiple cellular pathways were dysregulated in the NPC cells. Studies on the precancerous lesions revealed early genetic changes and a critical role of Epstein- Barr virus (EBV) latent infection in the development of this cancer.

MalaCards based summary : Nasopharyngeal Carcinoma, also known as malignant neoplasm of nasopharynx, is related to burkitt lymphoma and b-cell lymphoma, and has symptoms including headache, tinnitus and rhinorrhea. An important gene associated with Nasopharyngeal Carcinoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Viral carcinogenesis and Epstein-Barr virus infection. The drugs Erythromycin and Benzocaine have been mentioned in the context of this disorder. Affiliated tissues include lymph node, bone and liver, and related phenotype is neoplasia of the nasopharynx.

Disease Ontology : 12 A pharynx cancer that is located in the nasopharynx, the uppermost region of the pharynx or throat, where the nasal passages and auditory tubes join the remainder of the upper respiratory tract.

OMIM® : 57 Nasopharyngeal carcinoma (NPC, NPCA) is a multifactorial malignancy associated with both genetic and environmental factors. The cancer arises from the epithelium of the nasopharynx. The Epstein-Barr virus has been implicated (Tse et al., 2009). (607107) (Updated 20-May-2021)

Wikipedia : 73 Nasopharyngeal carcinoma (NPC), or nasopharynx cancer, is the most common cancer originating in the... more...

Related Diseases for Nasopharyngeal Carcinoma

Diseases in the Nasopharyngeal Carcinoma family:

Nasopharyngeal Carcinoma 2 Nasopharyngeal Carcinoma 3

Diseases related to Nasopharyngeal Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 631)
# Related Disease Score Top Affiliating Genes
1 burkitt lymphoma 31.7 TP53 PVT1 NFKBIA NEAT1
2 b-cell lymphoma 31.5 TP53 PVT1 NFKBIA MALAT1 HOTAIR GAS5
3 squamous cell carcinoma 31.5 TP53 NEAT1 MALAT1 HOTAIR FOXCUT CDKN2B-AS1
4 osteogenic sarcoma 31.4 XIST TP53 PVT1 NEAT1 MALAT1 HOTAIR
5 esophageal cancer 31.0 XIST TP53 PVT1 MIR100 MALAT1 LINC00460
6 squamous cell carcinoma, head and neck 30.9 TP53 NFKBIA MIR29C HOTAIR GAS5
7 thyroid carcinoma 30.9 PVT1 NEAT1 MALAT1 LINC00312 HOTAIR GAS5
8 bladder cancer 30.9 XIST TP53 PVT1 MIR29C MIR100 MALAT1
9 lung cancer susceptibility 3 30.8 TP53 NPTN-IT1 MALAT1 LINC-ROR HOTAIR GAS5
10 retinitis pigmentosa 11 30.8 XIST TP53 PVT1 NEAT1 HOTAIR
11 cervical cancer 30.8 TP53 PVT1 NPTN-IT1 NEAT1 MALAT1 HOTAIR
12 laryngeal squamous cell carcinoma 30.7 TP53 NEAT1 MALAT1 HOTAIR CDKN2B-AS1
13 renal cell carcinoma, nonpapillary 30.7 TP53 PVT1 PCAT7 NPTN-IT1 MIR29C MALAT1
14 melanoma 30.6 XIST TP53 PVT1 MIR100 MALAT1 LINC-ROR
15 oral squamous cell carcinoma 30.6 TP53 NEAT1 MIR100 MALAT1 HOTAIR FOXCUT
16 glioma 30.5 TP53 PVT1 NEAT1 MALAT1 HOTAIR GAS5
17 high grade glioma 30.4 XIST TP53 PVT1 NEAT1 MALAT1 LINC-ROR
18 thyroid cancer, nonmedullary, 1 30.4 PVT1 NEAT1 MALAT1 LINC-ROR HOTAIR
19 embryonal sarcoma 30.4 TP53 MALAT1
20 lung cancer 30.4 XIST TP53 PVT1 PCAT7 NFKBIA NEAT1
21 myeloma, multiple 30.4 TP53 PVT1 NFKBIA MALAT1 HOTAIR GAS5
22 gastric cancer 30.3 XIST TP53 PVT1 NPTN-IT1 NEAT1 MIR29C
23 hepatocellular carcinoma 30.3 XIST TP53 PVT1 NPTN-IT1 NFKBIA NEAT1
24 pancreatic cancer 30.3 XIST TP53 PVT1 NFKBIA NEAT1 MIR100
25 glioblastoma 30.1 XIST TP53 MALAT1 HOTAIR GAS5
26 colorectal cancer 30.1 XIST TP53 PVT1 NPTN-IT1 NFKBIA NEAT1
27 tongue squamous cell carcinoma 30.0 TP53 MALAT1 AFAP1-AS1
28 nasopharyngeal carcinoma 3 11.7
29 nasopharyngeal carcinoma 2 11.6
30 niemann-pick disease, type c1 11.5
31 lymphoepithelioma-like carcinoma 11.1
32 mucositis 11.0
33 neutropenia 10.9
34 nasopharyngitis 10.8
35 otitis media 10.7
36 dysphagia 10.7
37 ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus 10.7
38 thrombocytopenia 10.6
39 cranial nerve palsy 10.6
40 hypothyroidism 10.6
41 keratinizing squamous cell carcinoma 10.6
42 esophagus squamous cell carcinoma 10.6 TP53 NPTN-IT1 HOTAIR AFAP1-AS1
43 pfeiffer syndrome 10.5
44 sensorineural hearing loss 10.5
45 pancreatic ductal adenocarcinoma 10.5 TP53 PVT1 MIR29C MALAT1 HOTAIR AFAP1-AS1
46 dermatomyositis 10.5
47 cholangiocarcinoma 10.5 TP53 NEAT1 MALAT1 AFAP1-AS1
48 kidney cancer 10.5 TP53 PVT1 MIR29C MALAT1 HOTAIR GAS5
49 bladder urothelial carcinoma 10.5 TP53 PVT1 MALAT1 HOTAIR GAS5
50 undifferentiated embryonal sarcoma of the liver 10.5 TP53 MALAT1

Comorbidity relations with Nasopharyngeal Carcinoma via Phenotypic Disease Network (PDN):


Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Nasopharyngeal Carcinoma:



Diseases related to Nasopharyngeal Carcinoma

Symptoms & Phenotypes for Nasopharyngeal Carcinoma

Human phenotypes related to Nasopharyngeal Carcinoma:

31
# Description HPO Frequency HPO Source Accession
1 neoplasia of the nasopharynx 31 HP:0100630

Clinical features from OMIM®:

607107 (Updated 20-May-2021)

UMLS symptoms related to Nasopharyngeal Carcinoma:


headache; tinnitus; rhinorrhea

Drugs & Therapeutics for Nasopharyngeal Carcinoma

Drugs for Nasopharyngeal Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 307)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Erythromycin Approved, Investigational, Vet_approved Phase 4 114-07-8 12560
2
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
3
tannic acid Approved Phase 4 1401-55-4
4
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
5
Morphine Approved, Investigational Phase 4 57-27-2 5288826
6
Azithromycin Approved Phase 4 83905-01-5 55185 447043
7
Rofecoxib Approved, Investigational, Withdrawn Phase 4 162011-90-7 5090
8 Erythromycin Estolate Phase 4
9 Erythromycin stearate Phase 4
10 Erythromycin Ethylsuccinate Phase 4
11 Anti-Bacterial Agents Phase 4
12 Narcotics Phase 4
13 Analgesics, Opioid Phase 4
14 Anesthetics Phase 4
15 Anesthetics, General Phase 4
16 Anesthetics, Intravenous Phase 4
17 Cyclooxygenase 2 Inhibitors Phase 4
18 Cyclooxygenase Inhibitors Phase 4
19
Diphenhydramine Approved, Investigational Phase 3 147-24-0, 58-73-1 3100
20
Histamine Approved, Investigational Phase 3 51-45-6, 75614-87-8 774
21
Doxepin Approved, Investigational Phase 3 1668-19-5 667477 667468
22
Promethazine Approved, Investigational Phase 3 60-87-7 4927
23
Pilocarpine Approved, Investigational Phase 2, Phase 3 92-13-7, 54-71-7 5910
24
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
25
Ursodeoxycholic acid Approved, Investigational Phase 2, Phase 3 128-13-2 31401
26
Benralizumab Approved, Investigational Phase 3 1044511-01-4
27
Fluticasone Approved, Experimental Phase 3 90566-53-3 62924
28
nivolumab Approved Phase 3 946414-94-4
29
Oprelvekin Approved, Investigational Phase 3 145941-26-0
30
mometasone furoate Approved, Investigational, Vet_approved Phase 3 83919-23-7
31
Budesonide Approved Phase 3 51333-22-3 63006 5281004
32
Cisplatin Approved Phase 2, Phase 3 15663-27-1 84093 441203 2767
33
Paclitaxel Approved, Vet_approved Phase 2, Phase 3 33069-62-4 36314
34
Amifostine Approved, Investigational Phase 3 20537-88-6 2141
35
Acyclovir Approved Phase 3 59277-89-3 2022
36
Epirubicin Approved Phase 3 56420-45-2 41867
37
Tegafur Approved, Investigational Phase 3 17902-23-7 5386
38
Gemcitabine Approved Phase 3 95058-81-4 60750
39
Nedaplatin Approved, Investigational Phase 3 95734-82-0
40
Levoleucovorin Approved, Investigational Phase 3 68538-85-2 149436
41
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
42
Vinorelbine Approved, Investigational Phase 3 71486-22-1 60780 44424639
43
Celecoxib Approved, Investigational Phase 3 169590-42-5 2662
44
Fluorouracil Approved Phase 3 51-21-8 3385
45
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
46
Etoposide Approved Phase 3 33419-42-0 36462
47
Ifosfamide Approved Phase 3 3778-73-2 3690
48
leucovorin Approved Phase 3 58-05-9 6006
49
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
50 Endostar protein Phase 3

Interventional clinical trials:

(show top 50) (show all 599)
# Name Status NCT ID Phase Drugs
1 A Prospective, Randomized Controlled Open Research About the Impact of Nutritional Support on the Radiation Tolerance and Clinical Outcomes for Local Advanced Nasopharyngeal Carcinoma Patients Unknown status NCT02948699 Phase 4
2 Phase IV Clinical Trial of Nimotuzumab in the Treatment of Nasopharyngeal Carcinoma Unknown status NCT02293356 Phase 4 Nimotuzumab Injection
3 Clarify of Predictive Risk Factors of Chemotherapy-induced Liver Injury After Therapy With Docetaxel and Cisplatin for Nasopharyngeal Carcinoma Unknown status NCT03069820 Phase 4 docetaxel and cisplatin
4 Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutation in Familial Adenomatous Polyposis-protocol is Identical to Study No. 0519-10-TLV- Minors' Adjusted Version Unknown status NCT02354560 Phase 4 Erythromycin
5 Erythromycin as a Novel Therapy Against Familial Adenomatous Polyposis and Sporadic Colorectal Cancer by APC Nonsense Mutation Readthrough. Unknown status NCT02175914 Phase 4 Erythromycin
6 Enhancing Tobacco Use Treatment for African American Light Smokers Completed NCT00666978 Phase 4 bupropion hydrochloride
7 Comparing the Lozenge to the Patch for Smoking Cessation Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
8 Phase IV Clinical Study Evaluating The Efficacy of Chemoradiotherapy Following Neoadjuvant Treatment With Docetaxel and Cisplatin in Indifferentiated and Non-keratinized Squamous Cell Carcinoma of Nasopharynx Completed NCT00772681 Phase 4 docetaxel and cisplatin
9 Phase IV Trial to Use Stereotactic Body Radiotherapy for Head and Neck Tumors Completed NCT01344356 Phase 4
10 A Comparison of Oral Controlled-release Morphine With Transdermal Fentanyl in Nasopharyngeal Cancer Patients With Moderate or Severe Oral Mucositis Pain Induced by Chemoradiotherapy Not yet recruiting NCT04292990 Phase 4 Fentanyl;Morphine
11 Azithromycin Treatment for Readthrough of APC Gene Stop Codon Mutations in Familial Adenomatous Polyposis Not yet recruiting NCT04454151 Phase 4 Azithromycin Tablets
12 A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Rofecoxib in Familial Adenomatous Polyposis (FAP) Terminated NCT00140894 Phase 4 MK0966; rofecoxib / Duration of Treatment: 24 weeks;Comparator: placebo / Duration of Treatment: 24 weeks
13 The Effect of Celecoxib on Concurrent Chemoradiation With Weekly Nedaplatin in Nasopharyngeal Carcinoma Unknown status NCT02537925 Phase 3 Celecoxib;Nedaplatin
14 A Multicenter Trial Comparing Neoadjuvant Chemotherapy Followed by CCRT v.s. CCRT Alone in Locoregionally Advanced Nasopharyngeal Carcinoma Unknown status NCT00705627 Phase 3 neoadjuvant chemotherapy plus concurrent chemoradiotherapy
15 A Prospective,Randomized,Controlled,Multicenter,Phase III Study of Stage Ⅲ Study of Gemcitabine Plus Cisplatin With or Without Endostatin to the Metastatic Nasopharyngeal Carcinoma Unknown status NCT01915134 Phase 3 Recombinant Human Endostatin plus gemcitabine and cisplatin;Gemcitabine and cisplatin
16 A Single Center, Open-label, Randomized Controlled Clinical Trial on the Early and Whole Course Nutritional Support by Nutren® Optimum During Intensity Modulated Radiation Therapy for Nasopharyngeal Carcinoma Unknown status NCT03344068 Phase 2, Phase 3 Chemotherapy
17 A Randomized, Multicenter Phase III Clinical Trial Comparing Gemcitabine and Cisplatin With 5-Fluorouracil and Cisplatin in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) Unknown status NCT01528618 Phase 3 gemcitabine and cisplatin;5-Fluorouracil and cisplatin
18 A Prospective,Randomized,Double-Blind,Controlled,Multicenter,Phase III Study of Nimotuzumab in Combination With Chemotherapy and Radiotherapy for Patients With Local Advanced Nasopharyngeal Cancer Unknown status NCT01074021 Phase 3 Nimotuzumab;placebo plus chemoradiotherapy
19 A Multicenter, Randomized Controlled Phase III Clinical Trial of GP Induction Chemotherapy With TPF Adjuvant Chemotherapy Combined With DDP Concurrent Chemoradiotherapy in the Treatment of Locally Advanced Nasopharyngeal Carcinoma Unknown status NCT03604965 Phase 3 GP+CCRT;TPF+CCRT
20 A Multicenter Prospective Randomized Trial Comparing Concurrent Chemoradiotherapy Plus Adjuvant Chemotherapy With Concurrent Chemoradiotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma Unknown status NCT00677118 Phase 3 Cisplatin,fluorouracil;Cisplatin
21 Prospective Randomized Trial Comparing Induction Chemotherapy Plus Concurrent Chemoradiotherapy With Concurrent Chemoradiotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma Unknown status NCT01245959 Phase 3 Docetaxel, cisplatin and fluorouracil
22 A Randomized Phase III Study of Concurrent Weekly Nedaplatin or Cisplatin With IMRT in NPC Patients Unknown status NCT02301208 Phase 3 Nedaplatin;Cisplatin
23 Fine Needle Aspiration of Retropharyngeal Lymph Node Guided by Endoscopic Ultrasound for the Diagnosis of Patients With Suspected Recurrent Nasopharyngeal Carcinoma Unknown status NCT03006588 Phase 2, Phase 3
24 A Randomized Phase III Trial Evaluating Maintenance Chemotherapy for Metastatic Nasopharyngeal Carcinoma Unknown status NCT02944708 Phase 3 Conventional chemotherapy;Maintenance chemotherapy 1;Maintenance chemotherapy 2
25 A Multicenter, Prospective, Randomized Controlled Clinical Trial Comparing Endostar With Concurrent Chemoradiotherapy and Concurrent Chemoradiotherapy in the Treatment of Locoregionally Advanced Nasopharyngeal Carcinoma (NPC) Unknown status NCT02907710 Phase 3 Endostar;DDP
26 Prospective Randomized Trial Comparing Concurrent Chemoradiotherapy With or Without Induction Gemcitabine and Cisplatin in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma Unknown status NCT01872962 Phase 3 gemcitabine and cisplatin (Induction chemotherapy)
27 Combination of Cisplatin Plus Gemcitabine Induction Chemotherapy and Intensity-modulated Radiotherapy With or Without Concurrent Cisplatin for Locoregionally Advanced Nasopharyngeal Carcinoma Unknown status NCT01854203 Phase 2, Phase 3 Inductive chemotherapy + concurrent cisplatin and IMRT;Inductive chemotherapy + IMRT
28 A Multicenter Trial Evaluating the Efficacy and Safety of Nedaplatin Plus Docetaxel in Neoadjuvant Chemotherapy Followed by Nedaplatin in Concurrent Chemoradiation for Patients With Locoregionally Advanced Nasopharyngeal Carcinoma Unknown status NCT01479504 Phase 3 nedaplatin and docetaxel;cisplatin and docetaxel;nedaplatin and docetaxel;cisplatin and docetaxel
29 Cisplatin and 5-fluorouracil(PF) or Docetaxel,Cisplatin and 5-fluorouracil (TPF) Neoadjuvant Chemotherapy With Chemoradiation Therapy for Locally Advanced Nasopharyngeal Carcinoma--A Randomised Prospective Multicenter Phase 3 Study Unknown status NCT01536223 Phase 3 PF (cisplatin and 5-fluorouracil) group;TPF (docetaxel plus cisplatin and 5-fluorouracil) group
30 Recombine Endostatin in Alliance With Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma Unknown status NCT01689558 Phase 2, Phase 3 Recombine Endostatin
31 Aprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting Following High-dose Cisplatin in Nasopharyngeal Carcinoma Patients:a Randomized Phase 3 Trial Unknown status NCT02933099 Phase 3 Aprepitant+palonosetron+dexamethasone;palonosetron+dexamethasone
32 MULTICENTRIC INTERNATIONAL RANDOMIZED PHASE III TRIAL COMPARING, NEOADJUVANT CHEMOTHERAPY FOLLOWED BY STANDARD RADIOTHERAPY VERSUS THE SAME NEOADJUVANT CHEMOTHERAPY FOLLOWED BY STANDARD RADIOTHERAPY ASSOCIATED WITH DAILY HYDROXYUREA IN THE TREATMENT OF LOCALLY ADVANCED UNDIFFERENTIATED CARCINOMA NASOPHARYNGEAL TYPE. Unknown status NCT00180973 Phase 3 Hydroxyurea
33 Standard Radiotherapy Versus Concurrent Chemo-Radiotherapy Followed by Adjuvant Chemotherapy for Locally Advanced (Non-Metastatic) Nasopharyngeal Cancer Unknown status NCT00003637 Phase 3 cisplatin;fluorouracil
34 Efficiency of Ursodesoxycholic Acid in the Treatment of Duodenal Adenomas in Familial Adenomatous Polyposis Patients. URSOPAF Unknown status NCT00134758 Phase 2, Phase 3 Ursodeoxycholic acid;Placebo
35 A Pilot Study to Investigate the Efficacy and Safety of Buparid/PARI SINUS Versus Budes® Nasal Spray in the Therapy of Chronic Rhinosinusitis (CRS) With Polyposis Nasi in Adult Patients Unknown status NCT01946711 Phase 3 Budesonide;Budesonide
36 A Randomized Double-Blind Study of Doxepin Rinse Versus Placebo in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy Completed NCT01156142 Phase 3 doxepin hydrochloride
37 A Phase II/III Study Comparing Acupuncture-like Transcutaneous Electrical Nerve Stimulation (ALTENS) Versus Pilocarpine in Treating Early Radiation-Induced Xerostomia Completed NCT00656513 Phase 2, Phase 3 Pilocarpine
38 Phase III Trial of Low-level Laser Therapy to Prevent Induced Oral Mucositis in Head and Neck Cancer Patients Submitted to Concurrent Chemoradiation Completed NCT01439724 Phase 3
39 A Randomized Phase III Non-inferiority Study of Concurrent Chemoradiotherapy With Nedaplatin Versus Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma Completed NCT01540136 Phase 3 Nedaplatin;Cisplatin
40 A Phase III Study to Assess Conventional RT w/ Conventional Plus Accelerated Boost RT in the Treatment of Nasopharyngeal CA Completed NCT00535795 Phase 3
41 Maintenance Capecitabine Plus Best Supportive Care Versus Best Supportive Care for Metastatic Nasopharyngeal Carcinoma: a Multicenter, Randomised, Phase 3 Study. Completed NCT02460419 Phase 3 capecitabine
42 Late-Course Accelerated Hyperfractionated IMRT Versus Conventionally Fractionated IMRT in the Treatment of Locoregionally Advanced Nasopharyngeal Carcinoma: A Prospective Randomized Clinical Trial Completed NCT00778908 Phase 2, Phase 3 Concomitant cisplatin chemotherapy
43 Phase Ⅲ Study of Neoadjuvant TPF Chemotherapy Followed by Radiotherapy With Concurrent Nimotuzumab or Cisplatin for Locoregionally Advanced Nasopharyngeal Carcinoma (NPC). Completed NCT02012062 Phase 3 TPF neoadjuvant chemotherapy;Concurrent chemotherapy with cisplatin during radiotherapy;Concurrent nimotuzumab during radiotherapy
44 Randomized Trial to Evaluate Therapeutic Gain by Changing Chemoradiotherapy From Concurrent-adjuvant to Induction-concurrent Sequence, and Radiotherapy From Conventional to Accelerated Fractionation for Advanced Nasopharyngeal Carcinoma Completed NCT00379262 Phase 3 Capecitabine;Adjuvant chemotherapy using PF (5-Fluorouracil );Induction chemotherapy using PF (5-Fluorouracil)
45 A Multicenter Phase III Trial Comparing Induction Chemotherapy Followed by Concurrent Chemoradiotherapy Versus Concurrent Chemoradiotherapy Alone in Stage IV Nasopharyngeal Carcinoma (NPC) Completed NCT00201396 Phase 3 Mitomycin C,Epirubicin,Cisplatin,5-Fluorouracil,Leucovorin
46 A Phase III, Randomized, Placebo Controlled, Multicenter, Double-Blind Study Comparing Toripalimab Injection (JS001) Combined With Chemotherapy Versus Placebo Combined With Chemotherapy for Recurrent or Metastatic Nasopharyngeal Cancer Completed NCT03581786 Phase 3 Placebos
47 A Two-Arm Chemoprevention Trial in Familial Adenomatous Polyposis (FAP) Coli Patients Using the Purified Free Fatty Acid, Eicosapentaenoic Acid Completed NCT00510692 Phase 2, Phase 3 Eicosapentanoic Acid (EPA);Placebo
48 Prevention of Progression of Duodenal Adenomas to Cancer in Patients With Familial Adenomatous Polyposis (FAP) Completed NCT00808743 Phase 2, Phase 3 Celecoxib;Ursodeoxycholic acid;Placebo
49 A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study Of Benralizumab in Patients With Severe Nasal Polyposis Completed NCT03401229 Phase 3
50 A 16-Week Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Safety of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi Directional Device in Subjects With Bilateral Nasal Polyposis Followed by an 8-Week Open-Label Extension Phase to Assess Safety Completed NCT01622569 Phase 3 Fluticasone Propionate

Search NIH Clinical Center for Nasopharyngeal Carcinoma

Cochrane evidence based reviews: nasopharyngeal neoplasms

Genetic Tests for Nasopharyngeal Carcinoma

Genetic tests related to Nasopharyngeal Carcinoma:

# Genetic test Affiliating Genes
1 Nasopharyngeal Carcinoma 29 TP53

Anatomical Context for Nasopharyngeal Carcinoma

MalaCards organs/tissues related to Nasopharyngeal Carcinoma:

40
Lymph Node, Bone, Liver, Brain, Breast, T Cells, Endothelial

Publications for Nasopharyngeal Carcinoma

Articles related to Nasopharyngeal Carcinoma:

(show top 50) (show all 14787)
# Title Authors PMID Year
1
An infrequent point mutation of the p53 gene in human nasopharyngeal carcinoma. 61 6 57
1631151 1992
2
Whole-exome sequencing identifies MST1R as a genetic susceptibility gene in nasopharyngeal carcinoma. 6 61
26951679 2016
3
The genomic landscape of nasopharyngeal carcinoma. 61 57
24952746 2014
4
A genome-wide association study of nasopharyngeal carcinoma identifies three new susceptibility loci. 57 61
20512145 2010
5
Genome-wide association study reveals multiple nasopharyngeal carcinoma-associated loci within the HLA region at chromosome 6p21.3. 61 57
19664746 2009
6
A functional variant in the transcriptional regulatory region of gene LOC344967 cosegregates with disease phenotype in familial nasopharyngeal carcinoma. 61 57
16423998 2006
7
Association of PLUNC gene polymorphisms with susceptibility to nasopharyngeal carcinoma in a Chinese population. 57 61
15689457 2005
8
A rare polymorphism of the COX7B2 gene in a Cantonese family with nasopharyngeal carcinoma. 57 61
15623157 2004
9
Genome-wide scan for familial nasopharyngeal carcinoma reveals evidence of linkage to chromosome 4. 57 61
12118254 2002
10
Familial nasopharyngeal carcinoma. 61 57
6609336 1984
11
Familial clustering of nasopharyngeal carcinoma. 61 57
7191767 1980
12
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. 6
26619011 2016
13
Significance of Plk1 regulation by miR-100 in human nasopharyngeal cancer. 47 61
19739117 2010
14
Mutations clustered in exon 5 of the p53 gene in primary nasopharyngeal carcinomas from southeastern Asia. 57
7729941 1995
15
Candidate serological biomarkers for cancer identified from the secretomes of 23 cancer cell lines and the human protein atlas. 61 54
20124221 2010
16
[Tumor-targeted human telomerase reverse transcriptase promoter/tk gene therapy against human nasopharyngeal carcinoma cells in vitro]. 61 54
20423828 2010
17
Genetic polymorphisms of MDM2 and TP53 genes are associated with risk of nasopharyngeal carcinoma in a Chinese population. 61 54
20398418 2010
18
microRNA-141 is involved in a nasopharyngeal carcinoma-related genes network. 61 54
20053927 2010
19
Phosphatidylinositol 3-kinase inhibitor(LY294002) induces apoptosis of human nasopharyngeal carcinoma in vitro and in vivo. 61 54
20412566 2010
20
Expression of bcl-2 correlates with poor prognosis and modulates migration of nasopharyngeal carcinoma cells. 54 61
20036222 2010
21
Epstein-Barr virus encoded latent membrane protein 1 regulates mTOR signaling pathway genes which predict poor prognosis of nasopharyngeal carcinoma. 54 61
20338061 2010
22
Indole-3-carbinol inhibits nasopharyngeal carcinoma. 61 54
20335513 2010
23
[Study on the relationship between TK gene regulated by enhanced suicide gene vector and telomerase activity in nasopharyngeal carcinoma cells]. 54 61
20422982 2010
24
Regulation of hypoxia-induced mRNA expressions of HIF-1alpha and osteopontin and in vitro radiosensitization by tirapazamine in human nasopharyngeal carcinoma HNE-1 and CNE-1 cells. 61 54
20109337 2010
25
Bax inhibitor-1 mediates apoptosis-resistance in human nasopharyngeal carcinoma cells. 61 54
19579059 2010
26
Identification and characterization of the hypoxia-responsive element in human stanniocalcin-1 gene. 61 54
19628018 2010
27
A case-control and a family-based association study revealing an association between CYP2E1 polymorphisms and nasopharyngeal carcinoma risk in Cantonese. 54 61
19805575 2009
28
Targeted inhibition of the EGFR pathways enhances Zn-BC-AM PDT-induced apoptosis in well-differentiated nasopharyngeal carcinoma cells. 61 54
19816982 2009
29
Methylation associated inactivation of RASSF1A and its synergistic effect with activated K-Ras in nasopharyngeal carcinoma. 61 54
20042089 2009
30
PIK3CA amplification is predictive of poor prognosis in Tunisian patients with nasopharyngeal carcinoma. 61 54
19735264 2009
31
[Expression of HSP70/HSP27 protein in residual lesion after NPC radiotherapy]. 54 61
19952398 2009
32
[Induced RAS association domain family gene 1A gene expression by arsenic trioxide in nasopharyngeal carcinoma cell]. 54 61
20079060 2009
33
[Evaluation of combined determinations of Epstein-Barr virus antibodies for nasopharyngeal carcinoma assessed with receiver operating characteristic curve based on logistic regression]. 54 61
20387494 2009
34
LMP1-augmented kappa intron enhancer activity contributes to upregulation expression of Ig kappa light chain via NF-kappaB and AP-1 pathways in nasopharyngeal carcinoma cells. 54 61
19860880 2009
35
Role of p38 MAPKs in hypericin photodynamic therapy-induced apoptosis of nasopharyngeal carcinoma cells. 61 54
19496992 2009
36
[The relationship between the expression of EGFR NF-kappaB and radiosensitivity in human nasopharyngeal carcinoma]. 54 61
19947250 2009
37
ApoG2 induces cell cycle arrest of nasopharyngeal carcinoma cells by suppressing the c-Myc signaling pathway. 54 61
19698176 2009
38
IgA antibodies against the Epstein-Barr nuclear antigen1 as a valuable biomarker for the diagnosis of nasopharyngeal carcinoma in Tunisian patients. 61 54
19551836 2009
39
Regulation of RASSF1A in nasopharyngeal cells and its response to UV irradiation. 61 54
19450668 2009
40
[Expression of E-cadherin and P(120ctn) in nasopharyngeal carcinoma and their relationship]. 54 61
19894558 2009
41
[Association of nasopharyngeal carcinoma risk with cytochrome P450 CYP1A1 gene polymorphisms]. 54 61
19954069 2009
42
[Matrine enhances the cytotoxic sensitivity of ABCG2high nasopharyngeal carcinoma cells to natural killer cells by inducing high expression of NKG2D receptor ligands]. 54 61
19620045 2009
43
Epigenetic dysregulation of the host cell genome in Epstein-Barr virus-associated neoplasia. 61 54
19429479 2009
44
Close correlation between CXCR4 and VEGF expression and their prognostic implications in nasopharyngeal carcinoma. 61 54
19360294 2009
45
Curcuminoids suppress the growth of pharynx and nasopharyngeal carcinoma cells through induced apoptosis. 54 61
19317462 2009
46
[Association of CXCR4 and SDF-1alpha with organ-specific metastasis of nasopharyngeal carcinoma]. 54 61
19615279 2009
47
Nasopharyngeal carcinoma in Brunei Darussalam: low incidence among the Chinese and an evaluation of antibodies to Epstein-Barr virus antigens as biomarkers. 54 61
19421680 2009
48
GSTM1 and GSTT1 polymorphisms and nasopharyngeal cancer risk: an evidence-based meta-analysis. 54 61
19338664 2009
49
Expression modes and clinical manifestations of latent membrane protein 1, Ki-67, cyclin-B1, and epidermal growth factor receptor in nonendemic nasopharyngeal carcinoma. 54 61
19132724 2009
50
Inactivation of RASSF1A, RARbeta2 and DAP-kinase by promoter methylation correlates with lymph node metastasis in nasopharyngeal carcinoma. 54 61
19221469 2009

Variations for Nasopharyngeal Carcinoma

ClinVar genetic disease variations for Nasopharyngeal Carcinoma:

6 (show all 39)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 TP53 NM_000546.5(TP53):c.839G>C (p.Arg280Thr) SNV Pathogenic 12368 rs121912660 GRCh37: 17:7577099-7577099
GRCh38: 17:7673781-7673781
2 TP53 NM_000546.5(TP53):c.559+1G>A SNV Pathogenic 428908 rs1131691042 GRCh37: 17:7578370-7578370
GRCh38: 17:7675052-7675052
3 TP53 NM_000546.6(TP53):c.524G>A (p.Arg175His) SNV Pathogenic 12374 rs28934578 GRCh37: 17:7578406-7578406
GRCh38: 17:7675088-7675088
4 TP53 NM_000546.5(TP53):c.96+1G>T SNV Pathogenic 482212 rs1131691003 GRCh37: 17:7579699-7579699
GRCh38: 17:7676381-7676381
5 TP53 NM_000546.6(TP53):c.743G>A (p.Arg248Gln) SNV Pathogenic 12356 rs11540652 GRCh37: 17:7577538-7577538
GRCh38: 17:7674220-7674220
6 TP53 NM_000546.6(TP53):c.818G>A (p.Arg273His) SNV Pathogenic 12366 rs28934576 GRCh37: 17:7577120-7577120
GRCh38: 17:7673802-7673802
7 TP53 NM_000546.6(TP53):c.523C>T (p.Arg175Cys) SNV Likely pathogenic 245851 rs138729528 GRCh37: 17:7578407-7578407
GRCh38: 17:7675089-7675089
8 MST1R NM_002447.4(MST1R):c.917G>A (p.Arg306His) SNV risk factor 253185 rs200046052 GRCh37: 3:49940126-49940126
GRCh38: 3:49902693-49902693
9 NRAS NM_002524.5(NRAS):c.183A>T (p.Gln61His) SNV Likely pathogenic 373003 rs121913255 GRCh37: 1:115256528-115256528
GRCh38: 1:114713907-114713907
10 NRAS NM_002524.5(NRAS):c.182A>C (p.Gln61Pro) SNV Likely pathogenic 280409 rs11554290 GRCh37: 1:115256529-115256529
GRCh38: 1:114713908-114713908
11 NRAS NM_002524.5(NRAS):c.181C>A (p.Gln61Lys) SNV Likely pathogenic 73058 rs121913254 GRCh37: 1:115256530-115256530
GRCh38: 1:114713909-114713909
12 PIK3CA NM_006218.4(PIK3CA):c.1633G>A (p.Glu545Lys) SNV Likely pathogenic 13655 rs104886003 GRCh37: 3:178936091-178936091
GRCh38: 3:179218303-179218303
13 TP53 NM_000546.6(TP53):c.638G>A (p.Arg213Gln) SNV Likely pathogenic 135359 rs587778720 GRCh37: 17:7578211-7578211
GRCh38: 17:7674893-7674893
14 TP53 NM_000546.5(TP53):c.637C>G (p.Arg213Gly) SNV Likely pathogenic 376651 rs397516436 GRCh37: 17:7578212-7578212
GRCh38: 17:7674894-7674894
15 TP53 NM_000546.5(TP53):c.638G>C (p.Arg213Pro) SNV Likely pathogenic 231214 rs587778720 GRCh37: 17:7578211-7578211
GRCh38: 17:7674893-7674893
16 TP53 NM_000546.5(TP53):c.638G>T (p.Arg213Leu) SNV Likely pathogenic 376650 rs587778720 GRCh37: 17:7578211-7578211
GRCh38: 17:7674893-7674893
17 NRAS NM_002524.5(NRAS):c.182A>T (p.Gln61Leu) SNV Likely pathogenic 375874 rs11554290 GRCh37: 1:115256529-115256529
GRCh38: 1:114713908-114713908
18 HRAS , LRRC56 NM_005343.4(HRAS):c.34G>A (p.Gly12Ser) SNV Likely pathogenic 12602 rs104894229 GRCh37: 11:534289-534289
GRCh38: 11:534289-534289
19 NRAS NM_002524.5(NRAS):c.182A>G (p.Gln61Arg) SNV Likely pathogenic 13900 rs11554290 GRCh37: 1:115256529-115256529
GRCh38: 1:114713908-114713908
20 PIK3CA NM_006218.4(PIK3CA):c.1634A>C (p.Glu545Ala) SNV Likely pathogenic 13659 rs121913274 GRCh37: 3:178936092-178936092
GRCh38: 3:179218304-179218304
21 PIK3CA NM_006218.4(PIK3CA):c.1633G>C (p.Glu545Gln) SNV Likely pathogenic 375896 rs104886003 GRCh37: 3:178936091-178936091
GRCh38: 3:179218303-179218303
22 TP53 NM_000546.5(TP53):c.838A>G (p.Arg280Gly) SNV Likely pathogenic 376658 rs753660142 GRCh37: 17:7577100-7577100
GRCh38: 17:7673782-7673782
23 PIK3CA NM_006218.4(PIK3CA):c.1634A>G (p.Glu545Gly) SNV Likely pathogenic 13656 rs121913274 GRCh37: 3:178936092-178936092
GRCh38: 3:179218304-179218304
24 TP53 NM_000546.5(TP53):c.523C>G (p.Arg175Gly) SNV Likely pathogenic 376649 rs138729528 GRCh37: 17:7578407-7578407
GRCh38: 17:7675089-7675089
25 FGFR2 NM_000141.5(FGFR2):c.1645A>C (p.Asn549His) SNV Likely pathogenic 374821 rs1057519045 GRCh37: 10:123258036-123258036
GRCh38: 10:121498522-121498522
26 FGFR2 NM_000141.5(FGFR2):c.1647T>A (p.Asn549Lys) SNV Likely pathogenic 376157 rs121913476 GRCh37: 10:123258034-123258034
GRCh38: 10:121498520-121498520
27 HRAS , LRRC56 NM_005343.4(HRAS):c.35G>C (p.Gly12Ala) SNV Likely pathogenic 12603 rs104894230 GRCh37: 11:534288-534288
GRCh38: 11:534288-534288
28 FGFR2 NM_000141.5(FGFR2):c.1642A>C (p.Ile548Leu) SNV Likely pathogenic 376433 rs1057519901 GRCh37: 10:123258039-123258039
GRCh38: 10:121498525-121498525
29 HRAS , LRRC56 NM_005343.4(HRAS):c.34G>T (p.Gly12Cys) SNV Likely pathogenic 12613 rs104894229 GRCh37: 11:534289-534289
GRCh38: 11:534289-534289
30 PIK3CA NM_006218.4(PIK3CA):c.1635G>T (p.Glu545Asp) SNV Likely pathogenic 217293 rs121913275 GRCh37: 3:178936093-178936093
GRCh38: 3:179218305-179218305
31 TP53 NM_000546.5(TP53):c.839G>A (p.Arg280Lys) SNV Likely pathogenic 376657 rs121912660 GRCh37: 17:7577099-7577099
GRCh38: 17:7673781-7673781
32 TP53 NM_000546.5(TP53):c.839G>T (p.Arg280Ile) SNV Likely pathogenic 161517 rs121912660 GRCh37: 17:7577099-7577099
GRCh38: 17:7673781-7673781
33 FGFR2 NM_000141.5(FGFR2):c.1914T>A (p.Asn638Lys) SNV Likely pathogenic 376315 rs1057519854 GRCh37: 10:123247577-123247577
GRCh38: 10:121488063-121488063
34 TP53 NM_000546.5(TP53):c.839G>C (p.Arg280Thr) SNV Likely pathogenic 12368 rs121912660 GRCh37: 17:7577099-7577099
GRCh38: 17:7673781-7673781
35 TP53 NM_000546.5(TP53):c.799C>T (p.Arg267Trp) SNV Likely pathogenic 141764 rs55832599 GRCh37: 17:7577139-7577139
GRCh38: 17:7673821-7673821
36 TP53 NM_000546.6(TP53):c.847C>T (p.Arg283Cys) SNV Uncertain significance 127824 rs149633775 GRCh37: 17:7577091-7577091
GRCh38: 17:7673773-7673773
37 TP53 NM_000546.5(TP53):c.461G>A (p.Gly154Asp) SNV Uncertain significance 237950 rs762846821 GRCh37: 17:7578469-7578469
GRCh38: 17:7675151-7675151
38 TP53 NM_000546.5(TP53):c.466C>T (p.Arg156Cys) SNV Uncertain significance 127810 rs563378859 GRCh37: 17:7578464-7578464
GRCh38: 17:7675146-7675146
39 TP53 NM_000546.5(TP53):c.760A>G (p.Ile254Val) SNV Uncertain significance 406605 rs746601313 GRCh37: 17:7577521-7577521
GRCh38: 17:7674203-7674203

Cosmic variations for Nasopharyngeal Carcinoma:

9 (show top 50) (show all 195)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM143943797 TP53 skin,neck,carcinoma,squamous cell carcinoma c.266G>A p.R89Q 17:7674220-7674220 4
2 COSM142560281 TP53 skin,neck,carcinoma,squamous cell carcinoma c.626G>A p.R209Q 17:7674220-7674220 4
3 COSM144087106 TP53 skin,neck,carcinoma,squamous cell carcinoma c.266G>A p.R89Q 17:7674220-7674220 4
4 COSM144310203 TP53 skin,neck,carcinoma,squamous cell carcinoma c.626G>A p.R209Q 17:7674220-7674220 4
5 COSM142837352 TP53 skin,neck,carcinoma,squamous cell carcinoma c.743G>A p.R248Q 17:7674220-7674220 4
6 COSM145017657 TP53 skin,neck,carcinoma,squamous cell carcinoma c.626G>A p.R209Q 17:7674220-7674220 4
7 COSM105620276 TP53 skin,neck,carcinoma,squamous cell carcinoma c.743G>A p.R248Q 17:7674220-7674220 4
8 COSM143156843 TP53 skin,neck,carcinoma,squamous cell carcinoma c.266G>A p.R89Q 17:7674220-7674220 4
9 COSM122271559 TP53 skin,neck,carcinoma,squamous cell carcinoma c.347G>A p.R116Q 17:7674220-7674220 4
10 COSM106053189 TP53 skin,neck,carcinoma,squamous cell carcinoma c.743G>A p.R248Q 17:7674220-7674220 4
11 COSM143370869 TP53 skin,neck,carcinoma,squamous cell carcinoma c.626G>A p.R209Q 17:7674220-7674220 4
12 COSM111758576 TP53 skin,neck,carcinoma,squamous cell carcinoma c.743G>A p.R248Q 17:7674220-7674220 4
13 COSM112253622 TP53 skin,neck,carcinoma,squamous cell carcinoma c.743G>A p.R248Q 17:7674220-7674220 4
14 COSM93183630 TP53 skin,neck,carcinoma,squamous cell carcinoma c.743G>A p.R248Q 17:7674220-7674220 4
15 COSM144013367 TP53 skin,neck,carcinoma,squamous cell carcinoma c.710G>A p.R237Q 17:7674220-7674220 4
16 COSM144651115 TP53 skin,neck,carcinoma,squamous cell carcinoma c.626G>A p.R209Q 17:7674220-7674220 4
17 COSM87898351 TP53 skin,neck,carcinoma,squamous cell carcinoma c.743G>A p.R248Q 17:7674220-7674220 4
18 COSM121875983 TP53 skin,neck,carcinoma,squamous cell carcinoma c.347G>A p.R116Q 17:7674220-7674220 4
19 COSM122734176 TP53 skin,neck,carcinoma,squamous cell carcinoma c.347G>A p.R116Q 17:7674220-7674220 4
20 COSM133256111 TGFBR1 skin,neck,carcinoma,squamous cell carcinoma c.1040C>T p.S347F 9:99146601-99146601 4
21 COSM97906895 TGFBR1 skin,neck,carcinoma,squamous cell carcinoma c.1016C>T p.S339F 9:99146601-99146601 4
22 COSM135128838 TGFBR1 skin,neck,carcinoma,squamous cell carcinoma c.1259C>T p.S420F 9:99146601-99146601 4
23 COSM97922732 TGFBR1 skin,neck,carcinoma,squamous cell carcinoma c.1247C>T p.S416F 9:99146601-99146601 4
24 COSM84678061 SMO skin,neck,carcinoma,squamous cell carcinoma c.1103C>T p.P368L 7:129206332-129206332 4
25 COSM98728167 RARA skin,neck,carcinoma,squamous cell carcinoma c.1384C>T p.P462S 17:40356221-40356221 4
26 COSM107058787 RARA skin,neck,carcinoma,squamous cell carcinoma c.1093C>T p.P365S 17:40356221-40356221 4
27 COSM98724263 RARA skin,neck,carcinoma,squamous cell carcinoma c.1432C>T p.P478S 17:40356221-40356221 4
28 COSM86828717 RARA skin,neck,carcinoma,squamous cell carcinoma c.1384C>T p.P462S 17:40356221-40356221 4
29 COSM98707797 RARA skin,neck,carcinoma,squamous cell carcinoma c.1369C>T p.P457S 17:40356221-40356221 4
30 COSM94496058 RAD52 skin,neck,carcinoma,squamous cell carcinoma c.439G>A p.V147M 12:927173-927173 4
31 COSM133940534 RAD52 skin,neck,carcinoma,squamous cell carcinoma c.439G>A p.V147M 12:927173-927173 4
32 COSM107373333 RAD52 skin,neck,carcinoma,squamous cell carcinoma c.439G>A p.V147M 12:927173-927173 4
33 COSM130526023 RAD52 skin,neck,carcinoma,squamous cell carcinoma c.439G>A p.V147M 12:927173-927173 4
34 COSM96948694 PTPRT skin,neck,carcinoma,squamous cell carcinoma c.1619G>A p.G540E 20:42352227-42352227 4
35 COSM97161923 PTPRT skin,neck,carcinoma,squamous cell carcinoma c.1619G>A p.G540E 20:42352227-42352227 4
36 COSM96619514 PTPRT skin,neck,carcinoma,squamous cell carcinoma c.1619G>A p.G540E 20:42352227-42352227 4
37 COSM97161935 PTPRT skin,neck,carcinoma,squamous cell carcinoma c.1607C>T p.S536L 20:42352239-42352239 4
38 COSM144156675 PTPRT skin,neck,carcinoma,squamous cell carcinoma c.473G>A p.G158E 20:42352227-42352227 4
39 COSM96619533 PTPRT skin,neck,carcinoma,squamous cell carcinoma c.1607C>T p.S536L 20:42352239-42352239 4
40 COSM93273665 PTPRT skin,neck,carcinoma,squamous cell carcinoma c.1607C>T p.S536L 20:42352239-42352239 4
41 COSM96721565 PTPRT skin,neck,carcinoma,squamous cell carcinoma c.1619G>A p.G540E 20:42352227-42352227 4
42 COSM96835332 PTPRT skin,neck,carcinoma,squamous cell carcinoma c.1619G>A p.G540E 20:42352227-42352227 4
43 COSM142597931 PTPRT skin,neck,carcinoma,squamous cell carcinoma c.454C>T p.S152L 20:42352239-42352239 4
44 COSM144156682 PTPRT skin,neck,carcinoma,squamous cell carcinoma c.461C>T p.S154L 20:42352239-42352239 4
45 COSM97061657 PTPRT skin,neck,carcinoma,squamous cell carcinoma c.1619G>A p.G540E 20:42352227-42352227 4
46 COSM96835350 PTPRT skin,neck,carcinoma,squamous cell carcinoma c.1607C>T p.S536L 20:42352239-42352239 4
47 COSM96721578 PTPRT skin,neck,carcinoma,squamous cell carcinoma c.1607C>T p.S536L 20:42352239-42352239 4
48 COSM96948708 PTPRT skin,neck,carcinoma,squamous cell carcinoma c.1607C>T p.S536L 20:42352239-42352239 4
49 COSM93273656 PTPRT skin,neck,carcinoma,squamous cell carcinoma c.1619G>A p.G540E 20:42352227-42352227 4
50 COSM97061670 PTPRT skin,neck,carcinoma,squamous cell carcinoma c.1607C>T p.S536L 20:42352239-42352239 4

Copy number variations for Nasopharyngeal Carcinoma from CNVD:

7 (show all 41)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 72234 12 7764270 8036678 Duplication CLEC4C Nasopharyngeal cancer
2 72235 12 7764270 8036678 Duplication NANOG Nasopharyngeal cancer
3 72236 12 7764270 8036678 Duplication NANOGNB Nasopharyngeal cancer
4 72237 12 7764270 8036678 Duplication SLC2A14 Nasopharyngeal cancer
5 72238 12 7764270 8036678 Duplication SLC2A3 Nasopharyngeal cancer
6 126614 19 19848080 20497256 Deletion MIR1270 Nasopharyngeal cancer
7 126615 19 19848080 20497256 Deletion MIR1270 Nasopharyngeal cancer
8 126616 19 19848080 20497256 Deletion ZNF253 Nasopharyngeal cancer
9 126617 19 19848080 20497256 Deletion ZNF486 Nasopharyngeal cancer
10 126618 19 19848080 20497256 Deletion ZNF682 Nasopharyngeal cancer
11 126619 19 19848080 20497256 Deletion ZNF826P Nasopharyngeal cancer
12 126620 19 19848080 20497256 Deletion ZNF90 Nasopharyngeal cancer
13 126621 19 19848080 20497256 Deletion ZNF93 Nasopharyngeal cancer
14 132647 19 59423491 59445355 Deletion LILRA6 Nasopharyngeal cancer
15 171484 3 168801287 168851758 Amplification MECOM Nasopharyngeal cancer
16 171493 3 168867391 169381563 Amplification MECOM Nasopharyngeal cancer
17 177937 3 65166887 65190844 Deletion Nasopharyngeal cancer
18 197433 5 176843000 176857208 Deletion PDLIM7 Nasopharyngeal cancer
19 205127 6 121025447 121050579 Deletion Nasopharyngeal cancer
20 210827 6 31463047 31563588 Deletion HCG26 Nasopharyngeal cancer
21 210828 6 31463047 31563588 Deletion HCP5 Nasopharyngeal cancer
22 210829 6 31463047 31563588 Deletion MICA Nasopharyngeal cancer
23 210832 6 31463297 31559455 Deletion HCG26 Nasopharyngeal cancer
24 210836 6 31463297 31559455 Deletion HCP5 Nasopharyngeal cancer
25 210840 6 31463297 31559455 Deletion MICA Nasopharyngeal cancer
26 212636 6 4007991 32935606 Deletion PSMB9 Nasopharyngeal cancer
27 220654 7 140736 180194 Duplication CCDC146 Nasopharyngeal cancer
28 220655 7 140736 180194 Duplication Nasopharyngeal cancer
29 220656 7 140736 180194 Duplication LOC100133091 Nasopharyngeal cancer
30 220657 7 140736 180194 Duplication PMS2P11 Nasopharyngeal cancer
31 220658 7 140736 180194 Duplication POMZP3 Nasopharyngeal cancer
32 222456 7 152200000 154700000 Duplication Nasopharyngeal cancer
33 222457 7 152200000 154700000 Duplication Nasopharyngeal cancer
34 222532 7 153118877 153284978 Duplication Nasopharyngeal cancer
35 222533 7 153118877 153284978 Duplication Nasopharyngeal cancer
36 224029 7 2721151 3758564 Duplication CARD11 Nasopharyngeal cancer
37 224030 7 2721151 3758564 Duplication GNA12 Nasopharyngeal cancer
38 227304 7 66680598 66860844 Deletion AR Nasopharyngeal cancer
39 229234 7 892539 3753994 Duplication Nasopharyngeal cancer
40 236340 8 15447307 15475846 Deletion TUSC3 Nasopharyngeal cancer
41 256863 9 9780222 9786577 Deletion Nasopharyngeal cancer

Expression for Nasopharyngeal Carcinoma

Search GEO for disease gene expression data for Nasopharyngeal Carcinoma.

Pathways for Nasopharyngeal Carcinoma

Pathways related to Nasopharyngeal Carcinoma according to KEGG:

36
# Name Kegg Source Accession
1 Viral carcinogenesis hsa05203
2 Epstein-Barr virus infection hsa05169

Pathways related to Nasopharyngeal Carcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 9.88 TP53 LINC-ROR HOTAIR

GO Terms for Nasopharyngeal Carcinoma

Sources for Nasopharyngeal Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....